Skip to main content
OpenTrials
Completed

NCT Number: NCT07089693

Acute Kidney Injury in Critical COVID-19: Outcomes and Risks

This retrospective observational study aims to determine the incidence of acute kidney injury (AKI) associated with COVID-19, risk factors, and effects on mortality for intensive care unit patients. Data from 238 COVID-19 patients monitored in the Anesthesiology and Reanimation Intensive Care Unit of Ankara University Ibni Sina Hospital between January 1, 2021 and January 1, 2022 were retrospectively reviewed. Patients were divided into two groups according to the level of renal damage (with and without AKI). Those with AKI were staged per the KDIGO criteria (Stage 1-2-3). Demographic data, comorbidities, Charlson comorbidity indexes, Acute Physiology and Chronic Health Evaluation scores, laboratory results, and mortality data were examined. The data obtained were compared between the groups.

The findings may help improve clinical awareness and guide management strategies in intensive care unit patients with COVID-19 at risk of AKI

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID -19 Acute Kidney Injury COVID-19 Coronaviridae Infections Coronavirus Infections Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Infections Intensive Care Unit (ICU) Admission Kidney Diseases Lung Diseases Male Urogenital Diseases Mortality Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Renal Insufficiency Respiratory Tract Diseases Respiratory Tract Infections Urogenital Diseases Urologic Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara University

Ankara, 06230, Turkey (Türkiye)

About this study

This retrospective, single-center observational study was conducted at Ankara University Hospital. Data from 238 COVID-19 patients monitored in the Anesthesiology and Reanimation Intensive Care Unit of Ankara University Ibni Sina Hospital between January 1, 2021 and January 1, 2022 were retrospectively reviewed. The objective of the study was to investigate the frequency, risk factors, and impact on mortality of acute kidney injury (AKI) in adult patients hospitalized with confirmed COVID-19 infection.

Patients with a confirmed diagnosis of COVID-19 and available renal function data were included in the analysis. AKI was defined and staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Demographic characteristics, comorbidities, laboratory values, and clinical parameters were evaluated to identify potential risk factors for AKI development. The relationship between the presence and severity of AKI and in-hospital mortality was assessed.

The study aims to provide insight into the burden of COVID-19-associated AKI and to support improved clinical decision-making for identifying and managing high-risk patients in hospital settings.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Hospitalized patients with COVID-19 confirmed by PCR test
  • Required follow-up in the intensive care unit between January 1, 2021 and January 1, 2022

Exclusion criteria

  • Patients with end-stage renal disease (ESRD)
  • History of renal transplantation
  • Intensive care unit stay shorter than 48 hours

Treatment and study plan

Primary outcomes

  1. Intensive care unit mortality

    Time frame: From ICU admission until in-hospital death or ICU discharge, whichever occurs first, assessed up to 90 days.

    To evaluate whether the development of AKI is associated with mortality in COVID-19 patients monitored in the intensive care unit.

Secondary outcomes

  1. Length of intensive care unit stay

    Time frame: From ICU admission until ICU discharge, assessed up to 12 months.

    To assess whether the development of AKI in COVID-19 patients is associated with the length of stay in the intensive care unit.

  2. Incidence of acute kidney injury

    Time frame: From ICU admission until AKI diagnosis or ICU discharge, whichever occurs first, assessed during hospitalization (up to 100 days).

    To determine the incidence of AKI among COVID-19 patients, defined by the KDIGO criteria.

  3. Association between patient characteristics and AKI development

    Time frame: From ICU admission until AKI diagnosis or ICU discharge, assessed up to 100 days.

    To identify clinical and laboratory predictors associated with AKI development in COVID-19 patients requiring intensive care, using retrospective data analysis.

Sponsors and collaborators

Lead sponsor

Ankara University

Other

Registry information

Official study title

Determination of Risk Factors, Incidence and Mortality Rates of Acute Kidney Injury in COVID-19 Patients Hospitalized in Intensive Care Unit

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jul 28, 2025
Registry last updated
Jul 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.